Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 1/03/20 → 30/09/26 |
Funding
- Abbott Products Operations AG: A$683,010.00
Sympathoinhibition as a preferred second line treatment of obesity related hypertension
- Schlaich, Markus (Investigator 01)
- Carnagarin, Revathy (Investigator 02)
- Galindo Kiuchi, Marcio (Investigator 03)